![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DR Gehlert, LS Beavers, D Johnson, SL Gackenheimer, DA Schober and RA Gadski
Central Nervous System and Endocrine Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
The 36-amino acid peptide, neuropeptide Y (NPY), is a member of a peptide family that includes the endocrine peptides, peptide YY (PYY), and pancreatic polypeptide (PP). NPY receptors have been broadly subdivided into postsynaptic Y1 receptors and presynaptic Y2 receptors based on the preference of Pro34-substituted analogues for the Y1 receptors and carboxyl-terminal fragments for the Y2. A Y1 receptor has been cloned, and this receptor appears to mediate several effects of NPY, including vasoconstriction and anxiolysis in animal models. We report the cloning of a human brain Y2 receptor from a human brain library. Pools of clones were transiently expressed in COS-1 cells, and 125I-PYY binding pools were identified by autoradiography. After a single positive pool was detected in the original screening, a single clone was isolated by four rounds of sequential enrichment. The clone encoded a 381-amino acid protein of the heptahelix (seven TM) type. Amino acid identity of this receptor with the Y1 receptor was 31% overall with 40% identity in the TM regions. Comparison with the human PP1 receptor indicated 33% overall amino acid identity with 42% identity in the TM regions. Pharmacologically, the receptor exhibited high affinity for NPY, PYY, and carboxyl-terminal fragments of NPY and PYY. In addition, Pro34-substituted analogues had very low affinity. With the use of Northern blot analysis, high levels of Y2 mRNA were detected in a variety of brain regions with little expression in peripheral tissues. Thus, the receptor protein has the pharmacological properties and distribution of the human Y2 receptor.
This article has been cited by other articles:
|
|
 |
|
  P. Bonaventure, D. Nepomuceno, C. Mazur, B. Lord, D. A. Rudolph, J. A. Jablonowski, N. I. Carruthers, and T. W. Lovenberg Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1130 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Berglund, P. A. Hipskind, and D. R. Gehlert Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes Experimental Biology and Medicine, March 1, 2003; 228(3): 217 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sainsbury, C. Schwarzer, M. Couzens, S. Fetissov, S. Furtinger, A. Jenkins, H. M. Cox, G. Sperk, T. Hokfelt, and H. Herzog Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice PNAS, June 25, 2002; 99(13): 8938 - 8943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goumain, T. Voisin, A.-M. Lorinet, R. Ducroc, A. Tsocas, C. Roze, P. Rouet-Benzineb, H. Herzog, A. Balasubramaniam, and M. Laburthe The Peptide YY-Preferring Receptor Mediating Inhibition of Small Intestinal Secretion Is a Peripheral Y2 Receptor: Pharmacological Evidence and Molecular Cloning Mol. Pharmacol., July 1, 2001; 60(1): 124 - 134. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Schober, S. L. Gackenheimer, M. L. Heiman, and D. R. Gehlert Pharmacological Characterization of 125I-1229U91 Binding to Y1 and Y4 Neuropeptide Y/Peptide YY Receptors J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 275 - 280. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. C. Michel, A. Beck-Sickinger, H. Cox, H. N. Doods, H. Herzog, D. Larhammar, R. Quirion, T. Schwartz, and T. Westfall XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors Pharmacol. Rev., March 1, 1998; 50(1): 143 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jackerott and L.-I. Larsson Immunocytochemical Localization of the NPY/PYY Y1 Receptor in Enteric Neurons, Endothelial Cells, and Endocrine-like Cells of the Rat Intestinal Tract J. Histochem. Cytochem., December 1, 1997; 45(12): 1643 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Diez, J. Koistinaho, S. J. Dearmond, D. Groth, S. B. Prusiner, and T. Hokfelt Marked decrease of neuropeptide Y Y2 receptor binding sites in the hippocampus in murine prion disease PNAS, November 25, 1997; 94(24): 13267 - 13272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jackerott and L.-I. Larsson Immunocytochemical Localization of the NPY/PYY Y1 Receptor in the Developing Pancreas Endocrinology, November 1, 1997; 138(11): 5013 - 5018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, D. A. Dimaggio, S. P. Han, and T. C. Westfall Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1737 - H1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, T. Shi, K. Holmberg, M. Landry, W. Huang, H. Xiao, G. Ju, and T. Hokfelt Expression and regulation of the neuropeptide Y Y2 receptor in sensory and autonomic ganglia PNAS, January 21, 1997; 94(2): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gregor, Y. Feng, L. B. DeCarr, L. J. Cornfield, and M. L. McCaleb Molecular Characterization of a Second Mouse Pancreatic Polypeptide Receptor and Its Inactivated Human Homologue J. Biol. Chem., November 1, 1996; 271(44): 27776 - 27781. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
